Miyoshi N - Search Results

1

Impact of the COVID-19 pandemic on colorectal cancer surgery in Japan: Clinical Study Group of Osaka University-A multicenter retrospective study.

Miyo M, Mizushima T, Nishimura J, Hata T, Tei M, Miyake Y, Kagawa Y, Noura S, Ikenaga M, Danno K, Ogawa A, Chinen Y, Hata T, Miyoshi N, Takahashi H, Uemura M, Yamamoto H, Murata K, Doki Y, Eguchi H; Clinical Study Group of Osaka University Colorectal Group. Miyo M, et al. Among authors: miyoshi n. Ann Gastroenterol Surg. 2022 Aug 20;7(1):121-30. doi: 10.1002/ags3.12616. Online ahead of print. Ann Gastroenterol Surg. 2022. PMID: 36247513 Free PMC article.

2

A subsegmental pancreatectomy performed for carcinoma in situ limited to the proximal half of the pancreatic head with the aid of intraoperative 4-segment cytology for pancreatic juice--a case report.

Miyoshi N, Ishikawa O, Ohigashi H, Eguchi H, Imaoka S, Uehara H, Nakaizumi A, Takenaka A, Kasugai T. Miyoshi N, et al. Surgery. 2005 Nov;138(5):947-50. doi: 10.1016/j.surg.2005.05.005. Surgery. 2005. PMID: 16291397 No abstract available.

3

Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.

Miyoshi N, Yano M, Takachi K, Kishi K, Noura S, Eguchi H, Yamada T, Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Doki Y, Imaoka S. Miyoshi N, et al. J Surg Oncol. 2009 Apr 1;99(5):302-6. doi: 10.1002/jso.21235. J Surg Oncol. 2009. PMID: 19170110

4

RGS16 is a marker for prognosis in colorectal cancer.

Miyoshi N, Ishii H, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. Ann Surg Oncol. 2009 Dec;16(12):3507-14. doi: 10.1245/s10434-009-0690-3. Epub 2009 Sep 4. Ann Surg Oncol. 2009. PMID: 19760045

5

Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer.

Hoshino H, Miyoshi N, Nagai K, Tomimaru Y, Nagano H, Sekimoto M, Doki Y, Mori M, Ishii H. Hoshino H, et al. Among authors: miyoshi n. Biochem Biophys Res Commun. 2009 Dec 18;390(3):1061-5. doi: 10.1016/j.bbrc.2009.10.117. Epub 2009 Oct 25. Biochem Biophys Res Commun. 2009. PMID: 19861116

6

Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis.

Miyoshi N, Ishii H, Mimori K, Takatsuno Y, Kim H, Hirose H, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. Br J Cancer. 2009 Nov 17;101(10):1664-70. doi: 10.1038/sj.bjc.6605361. Br J Cancer. 2009. PMID: 19904274 Free PMC article.

7

Defined factors induce reprogramming of gastrointestinal cancer cells.

Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, Nagano H, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):40-5. doi: 10.1073/pnas.0912407107. Epub 2009 Dec 14. Proc Natl Acad Sci U S A. 2010. PMID: 20018687 Free PMC article.

8

TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.

Miyoshi N, Ishii H, Mimori K, Tanaka F, Hitora T, Tei M, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. Ann Surg Oncol. 2010 Apr;17(4):967-72. doi: 10.1245/s10434-009-0865-y. Epub 2009 Dec 22. Ann Surg Oncol. 2010. PMID: 20033322

9

SCRN1 is a novel marker for prognosis in colorectal cancer.

Miyoshi N, Ishii H, Mimori K, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. J Surg Oncol. 2010 Feb 1;101(2):156-9. doi: 10.1002/jso.21459. J Surg Oncol. 2010. PMID: 20039278

10

ATP11A is a novel predictive marker for metachronous metastasis of colorectal cancer.

Miyoshi N, Ishii H, Mimori K, Tanaka F, Nagai K, Uemura M, Sekimoto M, Doki Y, Mori M. Miyoshi N, et al. Oncol Rep. 2010 Feb;23(2):505-10. Oncol Rep. 2010. PMID: 20043114

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

701 results

Search Page

Filters